In Brief: Helionetics
This article was originally published in The Gray Sheet
Executive Summary
Helionetics: Submits investigational device exemption application to FDA to begin Phase I studies of its AccuLase excimer laser in transmyocardial revascularization procedures. Helionetics expects the two-site, 30-patient trial to begin this fall and be completed by January 1997...